Small Business: – Anti-infective therapeutics, diagnostic immunology, and decontamination – DCAI (14)
This special emphasis panel reviews small business applications in the general area of development of large molecule anti-infective therapeutics, on therapeutics directly targeting the immune response against microorganisms, and on diagnostic immunology. It also reviews applications proposing technologies to advance areas of microbial sterilization, disinfection, and bioremediation.
Review Dates
Topics
- Development and/or testing of novel anti-infective large molecule agents or therapeutic to fight infective agents
- Development of therapeutics directly targeting the immune response against microorganisms
- Therapeutic modulation of the immune system using biologics, adjuvants, cytokines, small molecules, antibodies, and proteins/peptides (e.g. sepsis treatment)
- Diagnostic immunology, including biomarkers, immunological markers, assays, and reagents for measuring innate and adaptive immune system function, immune-mediated diseases, and autoimmunity
- Advances in sterilization, decontamination, or disinfection technologies
Shared Interests and Overlaps:
There are shared interests with Biological Chemistry, Biophysics, and Assay Development [MCST (10)] in the area of assay development. Disease-agnostic assay development may be reviewed in MCST (10) while assay development focused on immune markers, immunoassays, or use of antibodies may be assigned to DCAI (14).
There are shared interests with Anti-Infective Therapeutics [DCAI (12)] in the development and/or testing of novel anti-infective agents or therapeutics. Small business applications focused on the development of large molecule therapeutics (e.g. peptides, antibodies), or therapeutics directly targeting microorganisms inducing a change in the immune responses, will be reviewed at DCAI 14. Small business applications focused on the development of small molecule therapeutics targeting the pathogen will be reviewed DCAI 12.
